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Abstract
Objective: To asses the adherence in daily clinical practice to a
guideline for anticoagulation during pregnancy.
Methods: The Dutch anticoagulation clinics developed a
pregnancy guideline for anticoagulant therapy in order to
avoid foetal exposure to coumarins between the 6th and 9th
week of gestation. Anticoagulation was studied in 282
prospectively-registered pregnant women, who were treated
by 26 different anticoagulation clinics.
Results: The guideline was adhered to in 93% of treated
women. Conforming to the guideline, the majority of patients
commenced anticoagulation with heparin in the first trimester
(n = 81) or started treatment from the second trimester
onwards (n = 168). At the time of conception, 31
anticoagulated women were on coumarin treatment. In 13 of
these patients (42%), coumarins were withdrawn before the
6th gestational week. In two pregnant women coumarin
therapy started unintentionally during the first trimester of
gestation.
Conclusion: The present study shows that the guideline under
study is useful in daily clinical practice. A careful instruction of
women of child-bearing age who need medication remains
important.
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Introduction
The Thalidomide tragedy dramatically demonstrated
the potential risks of medication during pregnancy.
Foetal exposure to drugs during critical periods of de-
velopment can result in structural anomalies, growth
restriction, and impaired development of the child.
Drug safety during gestation, therefore, remains an
important issue.
Anticoagulation during pregnancy must be care-
fully considered because of disadvantages for both
mother and child. Foetal exposure to coumarins from
the sixth to the ninth week may cause skeletal abnor-
malities, the so-called coumarin embryopathy. In ad-
dition, in utero exposure has been associated with
anomalies of the foetal nervous system1. In contrast to
coumarins, heparin does not cross the placenta and is
regarded as safe for the foetus. However, heparin
treatment has potentially adverse effects for the
mother, including osteoporosis after long-term ther-
apy, heparin-induced thrombocytopaenia and alo-
pecia2. Unfractionated or low-molecular-weight
heparin is, nowadays, used for most anticoagulant in-
dications. Its efficacy, however, in pregnant women
with prosthetic heart valves is questioned, therefore
coumarins are preferred for this indication3.
In the Netherlands, regional anticoagulation clinics
monitor oral anticoagulant therapy in out-patients. To
improve the safety of anticoagulation during preg-
nancy, the Federation of Dutch Anticoagulation Clin-
ics developed a ‘pregnancy guideline’. These recom-
mendations were published in the journal of the Fed-
eration in 19804. Nowadays, this guideline is brought
into practice in many European countries for anticoag-
ulation in pregnant women with prosthetic heart
valves5.
Together with the implementation of the guideline,
a prospective registration of anticoagulant therapy
during pregnancy was started. On the basis of this reg-
istry, we assessed the late effects of coumarins on
growth and development6. At the same time, we eval-
uated the adherence to the guideline in daily clinical
practice.
Materials and methods
Subjects
Women who were being treated with oral anticoagu-
lants during pregnancy were prospectively registered
by the Dutch anticoagulation clinics from 1980 on-
wards. In addition, we screened the central database
facility which automated anticoagulation clinics used
for routine care on ‘pregnancy’. Included in the study
were women treated with oral anticoagulants during
pregnancy between January 1982 and December
1990. Eligible women were approached by physicians
associated with the anticoagulation clinics, either di-
rectly or after consultation with the family’s general
practitioner. Participants were asked to sign a consent
form which included permission to look up medical
records from the time of pregnancy and delivery. The
study protocol was approved by the Medical Ethics
Committee of the University Hospital Groningen.
Pregnancy guideline
The guideline4 recommended to avoid the prescrip-
tion of coumarin derivatives between six and nine
weeks of gestation. During the first trimester of preg-
nancy, anticoagulation with heparin was advised (un-
til about the 14th week).
In women of child-bearing age who need long-term
therapy with coumarins, prescription of the short-act-
ing derivative acenocoumarol (Sintrom®) was recom-
mended. These women had to be instructed to
present for pregnancy testing as soon as possible, so
that coumarins could be replaced by heparin before
the sixth gestational week.
During the second and third trimester of pregnancy,
coumarin derivatives were regarded as the drugs of
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first choice for long-term anticoagulation. To avoid
bleeding complications around parturition, the short-
acting derivative acenocoumarol was preferred. The
guideline recommended to substitute heparin for cou-
marins from the 36th week onwards.
Methods
Information about anticoagulant therapy during preg-
nancy was obtained from the pregnancy registration,
and was completed with information from anticoagu-
lation clinics and medical records. We looked for data
about the indication of anticoagulant therapy, the pre-
scribed coumarin derivative, the date at which treat-
ment with heparin and coumarin derivatives was
started and withdrawn, and the date of delivery. The
first day of the last menstrual period was used as refer-
ence date for duration of pregnancy.
The analysis focussed on anticoagulant treatment
during three periods of pregnancy: a) the first trimes-
ter, including the time prior to conception; b) the sec-
ond and third trimester; and c) before expected child-
birth. Since pregnancy data do not follow a normal
distribution, statistics included the descriptive meas-
ures median, range and interquartile range of the ges-
tational weeks at which treatment was started and
withdrawn. Duration of treatment was expressed by
means and confidence intervals. The analyses were
carried out with the help of SPSS7.
Results
Subjects
In the period studied, 452 pregnant women were reg-
istered by 26 anticoagulation clinics; 314 were en-
rolled with a registration form and 138 women were
registered in the central database facility. Due to in-
complete personal data at the time of enrolment, 55
women could not be traced, and in 14 cases the gen-
eral practitioner discouraged contact with the family
because of social circumstances. From the remaining
383 women, 308 gave written informed consent (re-
sponse rate 80%). The mean age of the participating
womenwas 29 years (range 25 to 33 years). Exact data
about anticoagulant therapy during pregnancy could
be traced in 282 (92%) of these women. Indications
for anticoagulant therapy during pregnancy were
treatment (n  59) and prophylaxis (n  191) of
thromboembolic events, hereditary thrombophilia
(n  9), artificial heart valve (n  10), and a group of
incidental causes like antiphospholipid antibody syn-
drome, trauma, and surgery (n  8); for 6 cases the
indication was unknown.
Anticoagulation during the first trimester
During the first 14 weeks of gestation, 114 women
(40%) received anticoagulant treatment. Conforming
to the recommendation to avoid coumarins in this part
of pregnancy, the majority of these women (n  81)
received heparin.
However, 33 women were treated with coumarins,
31 of them using coumarin derivatives at the time of
conception (Figure 1). Indications comprised long-
term anticoagulant prophylaxis because of an artificial
heart valve (n  10), hereditary thrombophilia
(n  3), history of thromboembolic complications
(n  3), systemic lupus erythematosus with throm-
boembolic manifestations (n  1), and femoropop-
liteal bypass surgery (n  1) (Figure 1, cases 1 to 18).
In addition, 13 women conceived while they were on
treatment for a deep venous thrombosis (n  5) or
pulmonary embolism (n  8) (Figure 1, cases 19 to
31). In accordance with the recommendations, 27
(85%) pregnant mothers received the short-acting
coumarin derivative acenocoumarol.
Conforming to the guideline, coumarins were re-
placed by heparin before the 6th gestational week in
13 of 31 (42%) patients. In 16 women, heparin was
introduced in or after the 6th week, whereas in 2 (6%)
patients, acenocoumarol was not replaced by heparin
at all (Figure 1, cases 17 and 25).
Unfortunately, 2 patients started anticoagulant
prophylaxis with acenocoumarol during the first tri-
mester (Figure 1, cases 32 and 33). One of these
women was treated after orthopaedic trauma and sur-
gery. In this patient, treatment started in the 8th ges-
tational week and was withdrawn in the 12th week
when gestation was recognized.
Indications for anticoagulant therapy in the
heparin-treated patients (n  81) were treatment
(n  11) or prophylaxis (n  70) of thromboembolic
complications.
Anticoagulation during the second and third
trimester
Of the 114 women treated with anticoagulants during
the first trimester, 3 patients remained on heparin
therapy until the end of pregnancy and in 5 women
anticoagulation was withdrawn. Throughout the first
trimester 3 women continued coumarins; the remain-
ing 103 women resumed or started coumarin therapy
between the 11th and the 26th week of pregnancy
(median: 16th week; interquartile range 14th to 17th
week) (Figure 2). The week at which coumarins were
Figure 1 Coumarin use during the first trimester of
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resumed did not differ between the anticoagulation
clinics.
In addition, 168 women started anticoagulation
with coumarins in the second or third trimester of
pregnancy (Figure 2). The gestational age at which
coumarin therapy started in these pregnant mothers
ranged from 11 to 34 weeks (median: 21 weeks; inter-
quartile range 16 to 26 weeks). Indications included
treatment of a thromboembolic event during the cur-
rent pregnancy (n  48) or prophylaxis of throm-
boembolic complications in high-risk patients
(n  116). In four pregnant women, the indication
could not be traced.
Conforming to the recommendation to give prefer-
ence to the short-acting derivative, 234 (85%) of the
274 women were treated with acenocoumarol during
the second and third trimester. Phenprocoumon was
prescribed in 32 patients, 17 of which were treated by
the same anticoagulation clinic. This clinic prescribed
phenprocoumon in 17 of the 47 (36%) women they
treated. Six women switched derivative during preg-
nancy and in two cases the coumarin derivative could
not be traced.
The mean duration of coumarin prescription was 18
weeks (CI95: 17 to 19 weeks) for prophylactic and 11
weeks (CI95: 10 to 13 weeks) for therapeutic indica-
tions.
Withdrawal of coumarin treatment before parturition
In accordance with the guideline, in 266 (97%) of the
274 women coumarin treatment was discontinued be-
fore parturition started. The time at which coumarins
were withdrawn ranged from the 28th to the 40th
week with a median at the 36th week (Figure 2). We
found no differences between the anticoagulation
clinics. In 8 (3%) women, parturition started while
coumarins were not discontinued yet. In these
women, labour started prematurely at a median ges-
tational age of 35.5 weeks (range: 32 to 37 weeks).
After vitamin K suppletion, delivery was uncompli-
cated in all eight women.
Discussion
In our study, the clinical practice of anticoagulation
during pregnancy adhered very well to the stated rec-
ommendations. Clearly, an important part of the
guideline was to avoid coumarin exposure of the foe-
tus between the sixth and ninth week of gestation.
This was adhered to in 93% of the treated women. Of
the women who used coumarins at the time of con-
ception, substitution with heparin before the 6th week
succeeded in 42% of cases. This underscores the fact
that women on treatment with coumarins should be
extensively instructed about the foetal risks of cou-
marin derivatives and need to be encouraged to report
a pregnancy as soon as possible.
In a previous paper, we described a large cohort
study in which we investigated growth and long-term
development of coumarin-exposed children in com-
parison to non-exposed controls6. No major abnor-
malities were found. For the vast majority of children
there was no significant effect on growth and long-
term development. However, the risk for a combina-
tion of two or more minor abnormalities was higher
for the exposed children. In addition to this cohort
study, we evaluated the adherence to the used preg-
nancy guideline. Although the data are historic, we
feel they are still instructive since the recommenda-
tions of the guideline are used for some well-defined
indications during pregnancy. Heparin treatment car-
ries a substantial risk for both valve thrombosis and
bleeding complications in pregnant women with arti-
ficial heart valves3, 8. In this situation, coumarins are
preferred and the studied guideline is applied in many
European countries5, 9.
In the period studied, 71 anticoagulation clinics
served the Dutch population. The evaluation of adher-
ence to the pregnancy guideline included 26 clinics
extended over the country. Although this is a selection
of anticoagulation clinics, we feel their policy in clini-
cal practice did not differ from the other clinics. More-
over, they represent more than one third of all antico-
agulation clinics in The Netherlands.
In general, there is concern about the impact of
guidelines on physician behaviour. Important factors
that are known to influence physicians not to adhere
to guidelines include lack of familiarity with the guide-
line and lack of outcome expectancy of the stated rec-
ommendations10. Factors that could have contributed
to the high percentage of compliance in this study are
the thorough discussion with different medical experts
before elaboration and the publication of the guide-
line in a Dutch journal accessible to the target group
of physicians. In addition, the guideline did apply to a
specific clinical situation in which physicians are more
aware of the potential dangers of therapeutic strate-
gies.
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